Tirzepatide for Sleep Apnea: SURMOUNT-OSA Trial Results Summarized
Obstructive sleep apnea (OSA) affects an estimated 936 million adults worldwide, and its prevalence is tightly coupled with the obesity epidemic. The standard of care — continuous positive airway pressure (CPAP) therapy — is effective but plagued by poor adherence, with real-world usage rates often falling below 50%. Against this backdrop, the SURMOUNT-OSA trial program produced some of the most striking results in sleep medicine in recent years, demonstrating that tirzepatide, a dual GIP/GLP-1 receptor agonist, can dramatically reduce the severity of obstructive sleep apnea in adults with obesity.
The Rationale: Why Target Weight in Sleep Apnea?
Excess body weight is the single strongest modifiable risk factor for OSA. Fat deposition around the pharyngeal airway and tongue narrows the upper airway lumen, while abdominal adiposity reduces lung volumes and destabilizes respiratory control. Landmark data from the Wisconsin Sleep Cohort showed that a 10% weight gain predicted a ~32% increase in the apnea-hypopnea index (AHI), the primary metric of OSA severity (Peppard et al., 2000).
Previous studies with bariatric surgery have demonstrated that substantial weight loss can effectively resolve OSA in many patients (Greenburg et al., 2009). However, pharmacological approaches capable of producing surgery-level weight loss have only recently become available. Tirzepatide's demonstrated ability to produce >20% mean weight loss in the SURMOUNT-1 obesity trial (Jastreboff et al., 2022) made it a natural candidate for investigation in OSA.
SURMOUNT-OSA Trial Design
The SURMOUNT-OSA program consisted of two parallel, phase 3, double-blind, randomized, placebo-controlled trials conducted across multiple countries. Results were published in the New England Journal of Medicine in mid-2024 (Malhotra et al., 2024).
Both trials randomized participants to tirzepatide (escalated to a maximum of 10 or 15 mg weekly) or matching placebo for 52 weeks. The primary endpoint was the change from baseline in AHI as measured by polysomnography. Key secondary endpoints included body weight change, hypoxic burden, patient-reported sleepiness, high-sensitivity C-reactive protein (hsCRP), and systolic blood pressure.
Primary Results: AHI Reduction
The magnitude of AHI improvement was remarkable by any historical standard in pharmacotherapy for OSA.
In SURMOUNT-OSA 1 (the non-CPAP arm), tirzepatide reduced AHI by a mean of approximately 25.3 events/hour compared with 5.3 events/hour for placebo — a treatment difference of roughly 20 events/hour. This translated to about a 51% reduction in AHI from baseline in the tirzepatide group.
In SURMOUNT-OSA 2 (the CPAP adjunct arm), tirzepatide reduced AHI by approximately 29.3 events/hour compared with 5.5 for placebo, reflecting a treatment difference of about 23.8 events/hour.
Notably, over 40% of tirzepatide-treated participants in SURMOUNT-OSA 1 achieved disease resolution, defined as AHI <5 events/hour or AHI between 5–14 without significant symptoms. For a condition where pharmacotherapy had previously offered only marginal AHI reductions, these numbers represent a paradigm shift.
Weight Loss and Cardiometabolic Improvements
Consistent with earlier SURMOUNT trials, tirzepatide produced substantial weight loss:
Beyond weight and AHI, the trials reported impressive improvements across multiple cardiometabolic markers:
Patient-reported outcomes also improved. Scores on the Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance scale showed significant improvement, and Epworth Sleepiness Scale scores trended favorably in the tirzepatide arms, though sleepiness measures were less dramatically changed — likely because many participants had relatively mild subjective sleepiness at baseline.
How Tirzepatide Works: Dual Incretin Agonism
Tirzepatide is a 39-amino-acid synthetic peptide that acts as an agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor (Coskun et al., 2018). Its C20 fatty diacid moiety enables albumin binding, extending its half-life to approximately 5 days and permitting once-weekly dosing.
The dual agonism appears to produce weight loss that exceeds what GLP-1 receptor agonists alone achieve. Proposed mechanisms include:
In the context of OSA, weight loss reduces parapharyngeal fat pad volume, tongue fat, and abdominal adiposity — all mechanistically linked to airway collapsibility during sleep. Additionally, the anti-inflammatory effects of incretin agonism may independently benefit the systemic inflammation that characterizes both obesity and OSA (Drucker, 2018).
Limitations and Open Questions
While the SURMOUNT-OSA results are impressive, several important caveats deserve attention.
Trial duration was limited to 52 weeks. OSA is a chronic condition, and data from the SURMOUNT-5 weight management trial suggest some weight regain after tirzepatide discontinuation. Whether AHI reductions persist long-term — and what happens when treatment is stopped — remains unknown.
The study population was predominantly male and had relatively few participants with severe cardiovascular comorbidities. Whether the AHI reductions translate into hard cardiovascular outcomes (myocardial infarction, stroke, mortality) has not yet been established in this population, though separate cardiovascular outcome trials are underway.
Gastrointestinal side effects were common, consistent with the incretin agonist class. Nausea, diarrhea, and vomiting occurred more frequently with tirzepatide, though most events were mild to moderate and diminished over time. Approximately 10–14% of tirzepatide-treated participants discontinued due to adverse events across both trials.
Cost and access remain significant barriers. Tirzepatide (marketed as Mounjaro for type 2 diabetes and Zepbound for obesity) carries a substantial price tag, and insurance coverage for obesity-related indications varies widely. The FDA approved tirzepatide for moderate-to-severe OSA with obesity in late 2024 (FDA Press Release, 2024), but real-world access is still evolving.
Context: Comparison With Other Approaches
It's worth placing these results alongside other interventions:
Tirzepatide's ~20 event/hour treatment difference occupies a compelling middle ground — approaching surgical efficacy without the surgical risk, and substantially exceeding prior pharmacotherapy.